Skip to main content

Canaccord Genuity Reaffirms Their Buy Rating on Cardiol Therapeutics (CRDL)

Tipranks - Tipranks - Wed Oct 22, 2025

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Cardiol Therapeutics yesterday and set a price target of $8.00. The company’s shares closed yesterday at $1.05.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Nash is a 5-star analyst with an average return of 20.3% and a 51.36% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Cardiol Therapeutics.

Currently, the analyst consensus on Cardiol Therapeutics is a Strong Buy with an average price target of $8.80.

See the top stocks recommended by analysts >>

Based on Cardiol Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.35 million. In comparison, last year the company had a GAAP net loss of $6.59 million

Read More on CRDL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).